NorthLinks Bio
1 known investors
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral spray built on an engineered carbohydrate-binding module platform to block respiratory viruses at the point of entry. HEX17 is designed as a broad-spectrum prophylactic against pathogens including influenza, RSV, coronaviruses, and rhinoviruses, and has completed a Phase 2 human challenge study.
Investors · 1
In the news
Frequently asked questions
- What does NorthLinks Bio do?
- NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral spray built on an engineered carbohydrate-binding module platform to block respiratory viruses at the point of entry. HEX17 is designed as a broad-spectrum prophylactic against pathogens including influenza, RSV, coronaviruses, and rhinoviruses, and has completed a Phase 2 human challenge study.
- Who are NorthLinks Bio's investors?
- NorthLinks Bio's investors include RA Capital.